A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma (MCL) Interventions: Drug: Acalabrutinib; Drug: Venetoclax; Drug: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Condition: Relapsed/Refractory B-Cell Lymphoma Interventions: Drug: FT522; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Bendamustine Sponsor: Fate Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 18, 2023 Category: Research Source Type: clinical trials
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic; Small-Cell Lymphoma; Lymphoma, Small Lymphocytic; CLL; SLL Interventions: Drug: Nemtabrutinib; Drug: Venetoclax; Biological: Rituximab Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 17, 2023 Category: Research Source Type: clinical trials
